Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amryt Pharma Plc ADR (NQ: AMYT )

14.55 -0.04 (-0.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,680,383
Open 14.57
Bid (Size) 14.55 (4)
Ask (Size) 14.60 (2)
Prev. Close 14.59
Today's Range 14.55 - 14.60
52wk Range 6.410 - 14.77
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici
From Amryt Pharma plc
Via Globe NewsWire
Top 5 Health Care Stocks That Are Ticking Portfolio Bombs
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga

Performance

YTD
+100.97%
+100.97%
1 Month
-0.34%
-0.34%
3 Month
+104.64%
+104.64%
6 Month
+113.97%
+113.97%
1 Year
+79.41%
+79.41%

More News

Read More
AMYT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amryt Pharma Plc Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
AMRYT PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amryt Pharma Plc - AMYT
From Kahn Swick & Foti, LLC
Via Business Wire
Why Shares of Amryt Pharma Jumped This Week
Via The Motley Fool
AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023
From Amryt Pharma plc
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
Via Benzinga
AMRYT PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amryt Pharma Plc - AMYT
From Kahn Swick & Foti, LLC
Via Business Wire
S&P 500 Gains 0.6%; Albireo Pharma Shares Spike Higher
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Nasdaq Surges Over 200 Points; Crude Oil Rises 2%
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 10, 2023
Via Benzinga
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Tesla, Zillow, Albireo Pharma And Some Other Big Stocks Moving Higher On Monday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 9, 2023
Via Benzinga
US Stocks Open Higher; Dow Rises 150 Points
Via Benzinga
AMYT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amryt Pharma Plc Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Adobe To Rally 25%? Here Are 10 Other Analyst Forecasts For Monday
Via Benzinga
Italian Privately Held Chiesi Farmaceutici To Acquire Amryt Pharma For $1.25B
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why CinCor Pharma Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
From Amryt Pharma plc
Via Globe NewsWire
Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH
From Amryt Pharma plc
Via Globe NewsWire
COMP Adopts Positive Opinion on Orphan Designation for Mycapssa® for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors
From Amryt Pharma plc
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.